Aktuelle Rheumatologie, Table of Contents Aktuelle Rheumatologie 2013; 38(03): 180-183DOI: 10.1055/s-0033-1348315 Offene Korrespondenz © Georg Thieme Verlag KG Stuttgart · New York Gicht und andere Kristallarthropathien B. Manger 1 Medizinische Klinik 3, Universitätsklinikum Erlangen › Author Affiliations Recommend Article Abstract Buy Article Full Text References Literatur 1 Chohan S. Safety and efficacy of febuxostat treatment in subjects with gout and severe allopurinol adverse reactions. J Rheum 2011; 38: 1957-1959 2 Dalbeth N, McQueen FM, Singh JA et al. Tophus measurement as an outcome measure for clinical trials of chronic gout: progress and research priorities. J Rheum 2011; 38: 1458-1461 3 Goldfarb DS, McDonald PA, Hunt B et al. Febuxostat in gout: Serum urate response in uric acid overproducers and underexcretors. J Rheumatol 2011; 38: 1585-1589 4 Howard RG, Pillinger MH, Gyftopoulos S et al. Reproducibility of musculoskeletal ultrasound for determining monosodium urate deposition: concordance between readers. Arthritis Care Res 2011; 63: 1456-1462 5 Manger B, Lell M, Wacker J et al. Detection of periarticular urate deposits with dual energy CT in patients with acute gouty arthritis. Ann Rheum Dis 2012; 71: 470-472 6 Roddy E. Revisiting the pathogenesis of podagra: why does gout target the foot?. J Foot Ankle Res 2011; 4: 13 7 Singh JA, Hodges JS, Asch SM. Opportunities for improving medication use and monitoring in gout. Ann Rheum Dis 2009; 68: 1265-1270 8 Smith EUR, Diaz-Torne C, Perez-Ruiz F et al. Epidemiology of gout: an update. Best Pract Res Clin Rheumatol 2010; 24: 811-827 9 Soriano LC, Rothenbacher D, Choi HK et al. Contemporary epidemiology of gout in the UK general population. Arthritis Res Ther 2011; 13: R39 10 Stocker SL, Graham GG, McLachlan AJ et al. Pharmacokinetic and pharmacodynamic interaction between allopurinol and probenecid in patients with gout. J Rheumatol 2011; 38: 904-910 11 Sundy JS, Baraf HSB, Yood RA et al. Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment. JAMA 2011; 306: 711-720 12 Zhang W, Doherty M, Bardin T et al. European League Against Rheumatism recommendations for calcium pyrophosphate deposition. Part I: terminology and diagnosis. Ann Rheum Dis 2011; 70: 563-570 13 Zhang W, Doherty M, Pascual E et al. EULAR recommendations for calcium pyrophosphate deposition. Part II: management. Ann Rheum Dis 2011; 70: 571-575 14 Zhu Y, Pandya BJ, Choi HK. Prevalence of gout and hyperuricemia in the US general population. Arthritis Rheum 2011; 63: 3163-3141
